← Back to Screener
Sionna Therapeutics, Inc. Common Stock (SION)
Price$45.24
Favorite Metrics
Price vs S&P 500 (26W)54.22%
Price vs S&P 500 (4W)25.25%
Market Capitalization$2.03B
All Metrics
Book Value / Share (Quarterly)$6.86
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.49
Price vs S&P 500 (YTD)6.96%
EPS (TTM)$-1.70
10-Day Avg Trading Volume0.45M
EPS Excl Extra (TTM)$-1.70
EPS (Annual)$-1.88
ROI (Annual)-24.53%
Cash / Share (Quarterly)$5.27
ROA (Last FY)-23.09%
EBITD / Share (TTM)$-1.99
Cash Flow / Share (Annual)$-1.49
P/B Ratio6.61x
P/B Ratio (Quarterly)5.98x
Net Income / Employee (Annual)$-1
ROA (TTM)-21.71%
EPS Incl Extra (Annual)$-1.88
Current Ratio (Annual)20.61x
Quick Ratio (Quarterly)20.14x
3-Month Avg Trading Volume0.32M
52-Week Price Return406.06%
Revenue / Employee (TTM)$0
52-Week High$46.10
EPS Excl Extra (Annual)$-1.88
26-Week Price Return58.21%
Quick Ratio (Annual)20.14x
13-Week Price Return24.08%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)20.61x
Enterprise Value$1,970.512
Revenue / Employee (Annual)$0
Cash / Share (Annual)$5.27
3-Month Return Std Dev69.54%
Net Income / Employee (TTM)$-1
ROE (Last FY)-24.53%
EPS Basic Excl Extra (Annual)$-1.88
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.70
ROI (TTM)-22.87%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)376.23%
Year-to-Date Return9.60%
5-Day Price Return15.94%
EPS Normalized (Annual)$-1.88
Month-to-Date Return12.47%
EBITD / Share (Annual)$-2.20
EPS Basic Excl Extra (TTM)$-1.70
P/B Ratio (Annual)5.98x
Book Value / Share (Annual)$6.86
Price vs S&P 500 (13W)23.39%
Beta1.43x
Revenue / Share (TTM)$0.00
ROE (TTM)-22.87%
52-Week Low$7.76
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.21
4.21
4.19
4.19
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SIONSionna Therapeutics, Inc. Common Stock | — | — | — | — | $45.24 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Sionna Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for cystic fibrosis (CF), a progressive genetic disorder caused by mutations in the CFTR gene. The company's approach targets the disease mechanism by normalizing CFTR protein function to deliver clinically meaningful benefits. The company is entirely focused on CF drug development.